NCT01055379已完成4 期
A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study
Lundbeck Italia S.p.A.12 个研究点 分布在 1 个国家目标入组 121 人开始时间: 2010年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 121
- 试验地点
- 12
- 主要终点
- Change from baseline in BDI-IA total score
研究概览
简要总结
The primary endpoint for this study is the clinical response after 12 weeks of treatment, defined as a change in total score from baseline depressive symptoms as measured by the Beck Depression Inventory-Amended (BDI-IA) total score.
详细描述
ACCORDO is a multicentre, randomised, double-blind, and placebo-controlled study conducted in 12 Italian centres. Subjects are screened by means of the BDI-IA (cut-off 15) and randomised to treatment with rasagiline or placebo for 12 weeks.
Subjects have to be on stable treatment with dopaminergic agents at least 4 weeks before baseline, and maintained so during the course of the study.
The primary objective is to evaluate whether rasagiline compared to placebo improves depressive symptoms as evaluated by the BDI-IA total score.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatient, male or female aged >=40 and <80 years. The subject has a diagnosis of idiopathic Parkinson's Disease (PD) according to the United Kingdom Parkinson's Disease Society brain bank diagnostic criteria for PD for the clinical diagnosis of PD.
- •Depressive symptoms with a minimum severity of >=15 using the BDI-IA.
- •Hoehn and Yahr stage I-III.
- •Under stable (4 weeks prior to baseline) dopaminergic treatment without significant motor complication such as "on-off" phenomena and/or dyskinesia.
- •The subject and/or legal representative and/or impartial witness is/are able to read and understand the Subject Information Sheet.
- •The subject and/or legal representative has/have signed the Informed Consent Form (ICF) and if relevant the impartial witness has co-signed the ICF.
- •If female, must: agree not to try to become pregnant during the study (female patients of childbearing potential will take pregnancy test, using a urine stick), AND use adequate contraception (adequate contraception is defined as oral/systemic contraception, intrauterine device, diaphragm in combination with spermicidal, or condom for male partner in combination with spermicidal), OR have been menopausal for at least 24 months prior to baseline, (OR) have been surgically sterilised prior to baseline, OR have had a hysterectomy prior to baseline.
排除标准
- •A subject, who meets one or more of the following criteria at the Baseline Visit, is not eligible for inclusion in this study:
- •Motor complications such as wearing off and on-off phenomena.
- •Mini-Mental State Examination (MMSE) <26, corrected score.
- •Diagnosis of current or history of major depressive episode according to DSM-IV-TR® criteria within 1 year before recruitment into the study.
- •Presence of any other neurodegenerative disorder other than PD, based on judgement of investigator.
- •Psychotic symptoms, e.g. hallucination and delirium (determined by clinical evaluation).
- •Presence of any unstable or untreated systemic disorder such as diabetes, cardiac failure, or renal failure.
- •Use of any prohibited concomitant medication according to the timelines provided in Appendix II.
- •Patient who have undergone Deep Brain Stimulation surgery.
- •Current treatment with antidepressants or history of treatment with antidepressants less than 1 month prior to randomisation.
- •Current treatment or history of treatment less than 1 month prior to randomisation, with antipsychotics, cholinesterase inhibitors, memantine, amantadine, or anticholinergics.
- •Current treatment with selegiline or history of treatment with selegiline less than 90 days prior to randomisation.
研究组 & 干预措施
Rasagiline
Experimental
干预措施: Rasagiline (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in BDI-IA total score
时间窗: 12 weeks
次要结局
- Evaluate if rasagiline compared to placebo improves cognitive function, over a treatment period of 12 weeks in idiopathic Parkinson´s Disease, using a formal neuropsychiatric cognitive test battery; quality of life (PDQ 39); apathy; ADL, motor function(12 weeks)
- Change in quality of life using the PDQ-39 scale(12 weeks)
- Change in apathy using the Apathy Scale(12 weeks)
- Change in ADL and motor function using UPDRS scales part II and III, respectively(12 weeks)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
2 期
A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2Endocrine System DiseasesNutritional and Metabolic DiseasesDiabetes MellitusNCT00672386Johnson & Johnson Pharmaceutical Research & Development, L.L.C.352
已完成
不适用
Assessment of the Efficacy of Andrographis Paniculata in Subjects With Mild to Moderate OsteoarthritisKnee OsteoarthritisNCT03262792Vedic Lifesciences Pvt. Ltd.108
已完成
2 期
An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus InfectionHepatitis BNCT03361956Janssen Sciences Ireland UC232
已完成
3 期
Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime SymptomsModerate to Severe Idiopathic RLS With Daytime SymptomsNCT01112644Mundipharma Research GmbH & Co KG205
Unknown
2 期
A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.Hepatitis BNCT00044135Triangle Pharmaceuticals30